ECG with no c linically significant findings as assessed by the investigator . 6. No history of clinically significant autoimmune disease, HIV infection or other immunosuppressive disease. 7. ECOG (Eastern Cooperative Oncology G roup) perfor mance status of 0 -1. 28 Date: 8 April 2016 v 2.1 INO-3112 UPCC # 39313 / Inovio HPV -005 Inovio Pharmaceuticals, Inc Clinical Protocol 8. Women of childbearing potential must have a negative serum pregnancy test and agree to remain sexually abstinent, have a partner who is sterile (i.e., vasectomy), or use two medically effective methods of contraception (e.g. oral contr aception, barrier methods, spermicide, intrauterine device (IUD)). Males with reproductive potential must be willing to use a condom and have their female sexual partners use another form of contraception such as an IUD, spermicidal foam/gel/film/cream/sup pository, diaphragm with spermicide, oral contraceptive, injectable progesterone, sub- dermal implant or a tubal ligation if the female partner could become pregnant. This requirement should be followed from screening through 24 weeks after last dose of immunotherapy. 9. Able and willing to comply with all study procedures . 4.2 Exclusion Criteria 1. Pregnant or breast -feeding subjects. 2. Anticipated concomitant immunosuppressive therapy (excluding non- systemic inhaled, topical skin and/or eye drop- containing corticoster oids). 3. Any concurrent condition requiring the continued use of systemic steroids (>10 mg prednisone or equivalent per day, see above) or the use of immunosuppressive agents. All other corticosteroids must be discontinued at least 4 weeks prior to first dos e of study treatment. 4. Known history of hepatitis B or C with active viral replication. 5. Administration of any vaccine within 6 weeks of first dose of study treatment. 6. Tattoos, scars, or active lesions/rashes within 2 cm of the intended site of injection or if there is implanted metal within the same limb. Any device implanted in the chest (e.g., cardiac pacemaker or defibrillator) excludes the use of the deltoid muscle on the same side of the body. 7. Participation in another interventional clinical trial within 30 days before receiving first dose of study treatment. However, the subject may participate in an observational studies .